444 related articles for article (PubMed ID: 17906076)
1. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
Tai YT; Dillon M; Song W; Leiba M; Li XF; Burger P; Lee AI; Podar K; Hideshima T; Rice AG; van Abbema A; Jesaitis L; Caras I; Law D; Weller E; Xie W; Richardson P; Munshi NC; Mathiot C; Avet-Loiseau H; Afar DE; Anderson KC
Blood; 2008 Aug; 112(4):1329-37. PubMed ID: 17906076
[TBL] [Abstract][Full Text] [Related]
2. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Hsi ED; Steinle R; Balasa B; Szmania S; Draksharapu A; Shum BP; Huseni M; Powers D; Nanisetti A; Zhang Y; Rice AG; van Abbema A; Wong M; Liu G; Zhan F; Dillon M; Chen S; Rhodes S; Fuh F; Tsurushita N; Kumar S; Vexler V; Shaughnessy JD; Barlogie B; van Rhee F; Hussein M; Afar DE; Williams MB
Clin Cancer Res; 2008 May; 14(9):2775-84. PubMed ID: 18451245
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
van Rhee F; Szmania SM; Dillon M; van Abbema AM; Li X; Stone MK; Garg TK; Shi J; Moreno-Bost AM; Yun R; Balasa B; Ganguly B; Chao D; Rice AG; Zhan F; Shaughnessy JD; Barlogie B; Yaccoby S; Afar DE
Mol Cancer Ther; 2009 Sep; 8(9):2616-24. PubMed ID: 19723891
[TBL] [Abstract][Full Text] [Related]
4. In vivo anti-tumor efficacy of afucosylated anti-CS1 monoclonal antibody produced in glycoengineered Pichia pastoris.
Gomathinayagam S; Laface D; Houston-Cummings NR; Mangadu R; Moore R; Shandil I; Sharkey N; Li H; Stadheim TA; Zha D
J Biotechnol; 2015 Aug; 208():13-21. PubMed ID: 26015261
[TBL] [Abstract][Full Text] [Related]
5. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.
Tai YT; Soydan E; Song W; Fulciniti M; Kim K; Hong F; Li XF; Burger P; Rumizen MJ; Nahar S; Podar K; Hideshima T; Munshi NC; Tonon G; Carrasco RD; Afar DE; Anderson KC
Blood; 2009 Apr; 113(18):4309-18. PubMed ID: 19196658
[TBL] [Abstract][Full Text] [Related]
6. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.
Collins SM; Bakan CE; Swartzel GD; Hofmeister CC; Efebera YA; Kwon H; Starling GC; Ciarlariello D; Bhaskar S; Briercheck EL; Hughes T; Yu J; Rice A; Benson DM
Cancer Immunol Immunother; 2013 Dec; 62(12):1841-9. PubMed ID: 24162108
[TBL] [Abstract][Full Text] [Related]
7. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.
Tai YT; Li X; Tong X; Santos D; Otsuki T; Catley L; Tournilhac O; Podar K; Hideshima T; Schlossman R; Richardson P; Munshi NC; Luqman M; Anderson KC
Cancer Res; 2005 Jul; 65(13):5898-906. PubMed ID: 15994968
[TBL] [Abstract][Full Text] [Related]
8. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.
Veillette A; Guo H
Crit Rev Oncol Hematol; 2013 Oct; 88(1):168-77. PubMed ID: 23731618
[TBL] [Abstract][Full Text] [Related]
9. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells.
Chu J; He S; Deng Y; Zhang J; Peng Y; Hughes T; Yi L; Kwon CH; Wang QE; Devine SM; He X; Bai XF; Hofmeister CC; Yu J
Clin Cancer Res; 2014 Aug; 20(15):3989-4000. PubMed ID: 24677374
[TBL] [Abstract][Full Text] [Related]
10. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
Balasa B; Yun R; Belmar NA; Fox M; Chao DT; Robbins MD; Starling GC; Rice AG
Cancer Immunol Immunother; 2015 Jan; 64(1):61-73. PubMed ID: 25287778
[TBL] [Abstract][Full Text] [Related]
11. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.
Chu J; Deng Y; Benson DM; He S; Hughes T; Zhang J; Peng Y; Mao H; Yi L; Ghoshal K; He X; Devine SM; Zhang X; Caligiuri MA; Hofmeister CC; Yu J
Leukemia; 2014 Apr; 28(4):917-27. PubMed ID: 24067492
[TBL] [Abstract][Full Text] [Related]
12. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
13. CS1-directed monoclonal antibody therapy for multiple myeloma.
Benson DM; Byrd JC
J Clin Oncol; 2012 Jun; 30(16):2013-5. PubMed ID: 22547601
[No Abstract] [Full Text] [Related]
14. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Tai YT; Fulciniti M; Hideshima T; Song W; Leiba M; Li XF; Rumizen M; Burger P; Morrison A; Podar K; Chauhan D; Tassone P; Richardson P; Munshi NC; Ghobrial IM; Anderson KC
Blood; 2007 Sep; 110(5):1656-63. PubMed ID: 17510321
[TBL] [Abstract][Full Text] [Related]
15. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.
Podar K; Zimmerhackl A; Fulciniti M; Tonon G; Hainz U; Tai YT; Vallet S; Halama N; Jäger D; Olson DL; Sattler M; Chauhan D; Anderson KC
Br J Haematol; 2011 Nov; 155(4):438-48. PubMed ID: 21923653
[TBL] [Abstract][Full Text] [Related]
16. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
Azab AK; Runnels JM; Pitsillides C; Moreau AS; Azab F; Leleu X; Jia X; Wright R; Ospina B; Carlson AL; Alt C; Burwick N; Roccaro AM; Ngo HT; Farag M; Melhem MR; Sacco A; Munshi NC; Hideshima T; Rollins BJ; Anderson KC; Kung AL; Lin CP; Ghobrial IM
Blood; 2009 Apr; 113(18):4341-51. PubMed ID: 19139079
[TBL] [Abstract][Full Text] [Related]
17. MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide.
Asvadi P; Cuddihy A; Dunn RD; Jiang V; Wong MX; Jones DR; Khong T; Spencer A
Br J Haematol; 2015 May; 169(3):333-43. PubMed ID: 25653020
[TBL] [Abstract][Full Text] [Related]
18. Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.
Zhang M; Qian J; Lan Y; Lu Y; Li H; Hong B; Zheng Y; He J; Yang J; Yi Q
Int J Cancer; 2014 Sep; 135(5):1132-41. PubMed ID: 24474467
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
Campbell KS; Cohen AD; Pazina T
Front Immunol; 2018; 9():2551. PubMed ID: 30455698
[TBL] [Abstract][Full Text] [Related]
20. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
Ikeda H; Hideshima T; Fulciniti M; Lutz RJ; Yasui H; Okawa Y; Kiziltepe T; Vallet S; Pozzi S; Santo L; Perrone G; Tai YT; Cirstea D; Raje NS; Uherek C; Dälken B; Aigner S; Osterroth F; Munshi N; Richardson P; Anderson KC
Clin Cancer Res; 2009 Jun; 15(12):4028-37. PubMed ID: 19509164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
